Novel GLP-1-based Medications for Type 2 Diabetes and Obesity Abstract The approvals of semaglutide and tirzepatide have set new benchmarks in the treatment of type 2 diabetes and obesity Building on their success, novel glucagon-like peptide-1 (GLP-1)-based therapeutics are rapidly advancing
New Formulations of GLP-1s Demonstrate Positive Results, Potentially . . . Glucagon-like peptide-1 (GLP-1) receptor agonists are a well-established treatment option for obesity and type 2 diabetes However, there is a growing need for additional options to meet patient preferences and ensure tailored care, such as oral forms or injectables with less frequent dosing
What’s Next in Diabetes Care: Innovations and Insights From expanding treatment options to groundbreaking research, progress is happening With each breakthrough, we move closer to better care, improved quality of life and—one day—a cure